Stevenage Bioscience Catalyst (SBC) has announced that Dr. Sally Ann Forsyth is set to join the company as CEO in March 2018.
Late-stage pharmaceuticals financing and co-development specialist Avillion LLP has named Kathryn J. Gregory Chief Business Officer.
Symcel announced that Jesper Ericsson has joined Symcel as Chief Executive Officer.
Belgian diagnostics company MDxHealth SA has appointed Michael K. Brawer, MD as Chief Medical Officer to prepare the company for growth in H2/17 and beyond. The urologist and former professor of urology and pathology has over 25 years of experience in the industry leading clinical affairs in urology for diagnostic and pharmaceutical companies. Before joining MDx Health, Brawer served as Vice President of Medical Affairs, Urology at Myriad Genetics where he led all clinical aspects of development, education and commercialisation of Myriad’s prognostic prostate cancer assay. Prior to that, he held senior positions for GTx Inc, Tokai Pharmaceuticals and Threshold Pharmaceuticals. "Dr. Brawer’s arrival rounds out our 2017 campaign to expand our executive team, alongside our goal to nearly double our US sales force, in preparation for a sustained growth phase", commented Dr. Jan Groen, CEO, MDxHealth.
Swedish specialty pharmaceutical company Pharmalink AB Stockholm has Fredrik Johansson as new Chief Financial Officer.
Gene therapy specialist Orchard Therapeutics (London) has appointed Mark Rothera as President and Chief Executive Officer, a specialist for the commercialisation of novel treatments and business development.
Gene therapy specialist Uniqure NV announced new executive appointments to its leadership team and nominations to its Board of Directors. Scott McMillan, for instance, will be responsible for all current Good Manufacturing Process (cGMP) activities and all product development functions.
In preparation for the development and commercialisation of Autolus T-cell products, the London based company announced four new senior leadership appointments.
Following Novo Nordisk, Dr. Stanislav Glezer has joined the French biopharmaceutical company Adocia as the new Chief Medical Officer. He will be responsible for designing and executing the clinical development plan of its diabetes treatments.
Swiss-based pharmaceutical company Myovant Sciences Ltd. is adding four new executives. Among them is a new Chief Medical Director, Juan Camilo Arjona Ferreira. In addition, the company increases its competence in regulatory affairs.